Romiplostim for Thrombocytopenia in Leukemia Patients

This clinical trial investigates the use of Romiplostim for treating cancer treatment-induced thrombocytopenia (CTIT) in adults with leukemia. CTIT is a condition where platelet levels drop due to cancer treatments, increasing the risk of bleeding and potentially limiting treatment options. Current management includes platelet transfusions and thrombopoietic agents, but there is limited research on Romiplostim's effectiveness in leukemia patients. By studying this medication, researchers hope to find new ways to manage CTIT, improve treatment outcomes, and enhance the quality of life for patients undergoing cancer therapy. In this phase 2 interventional study, participants receive Romiplostim to assess its effectiveness and safety in increasing platelet counts and reducing bleeding risks. Participants are closely monitored to evaluate how well the drug works in preventing the need for platelet transfusions and managing CTIT. The study focuses on understanding the benefits and any potential side effects of Romiplostim, aiming to establish it as a viable treatment option for leukemia patients experiencing low platelet counts due to cancer treatments.